Bridgeway Capital Management’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Bridgeway Capital Management’s Portfolio ETTX Stock Details ETTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-132,600	Closed	-$292K	–	1483
2022 Q2	$292K	Hold	132,600	–	–	0.01%	1000
2022 Q1	$248K	Buy	132,600 +22,600	+21%	+$41.1K	﹤0.01%	1129
2021 Q4	$241K	Hold	110,000	–	–	﹤0.01%	1136
2021 Q3	$367K	Hold	110,000	–	–	0.01%	1121
2021 Q2	$294K	Sell	110,000 -10,000	-8%	-$22.6K	0.01%	1213
2021 Q1	$257K	Hold	120,000	–	–	﹤0.01%	1255
2020 Q4	$296K	Buy	120,000 +50,000	+71%	+$98.3K	0.01%	1124
2020 Q3	$143K	Hold	70,000	–	–	﹤0.01%	1225
2020 Q2	$207K	Buy	70,000 +35,000	+100%	+$95.7K	﹤0.01%	1142
2020 Q1	$89K	Buy	+35,000	New	+$158K	﹤0.01%	1185

Bridgeway Capital Management's ETTX Position: Q3 2022 in Review

Bridgeway Capital Management sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 132,600 shares — an estimated $292K sold.

Bridgeway Capital Management first reported a position in ETTX in Q1 2020 and held it in 10 quarters. The position peaked at $367K in Q3 2021. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.

Bridgeway Capital Management reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
Bridgeway Capital Management sold 132,600 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $292K.
Bridgeway Capital Management first reported a position in Entasis Therapeutics Holdings Inc. in Q1 2020 and held it in 10 quarters.
Bridgeway Capital Management's Entasis Therapeutics Holdings Inc. position peaked at $367K in Q3 2021.
0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.

Based on Bridgeway Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.